DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Abstract

DEAD box helicase 3, X-linked (DDX3X) is an ATP-dependent RNA helicase and is involved in multiple cancer-related cellular processes, including transcriptional regulation, cell adhesion, signal transduction and stemness [3]. Recurrent DDX3X mutations in DLBCL are associated with worse clinical outcomes Navigation through NHL patient samples in the cBioPortal [4] database revealed that DDX3X was mutated in 49 out of 1343 (3.6%) DLBCL cases. [...]available database in the ICGC [5] and the COSMIC [6] portals revealed mutations in DDX3X in 63 out of 1319 (4.7%) and 160 out of 5160 (3.1%) DLBCL cases, respectively. Besides DLBCL, DDX3X was also recurently mutated in other NHL subtypes, including Burkitt lymphoma (BL) and NKTCL [7]. S7), suggesting that STAT3 hyperphosphorylation is a downstream effect of DDX3X lesions. [...]DDX3X mutation/depletion in NHL subtypes (DLBCL, NKTCL, CTCL) significantly increased the phosphorylation of p42/44 MAPK (Fig. 2E).